{"id":982776,"date":"2026-07-20T09:41:18","date_gmt":"2026-07-20T13:41:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"},"modified":"2026-07-20T09:41:18","modified_gmt":"2026-07-20T13:41:18","slug":"oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","title":{"rendered":"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026"},"content":{"rendered":"
\n

\n Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC<\/em>\n <\/p>\n

\n Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone<\/em>\n <\/p>\n

\n Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.<\/p>\n

\n
\n Poster presentation details:<\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nEnozertinib (ORIC-114), a Brain Penetrant, Highly Selective\u00a0EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n2627P<\/td>\n<\/tr>\n
\n Session Date & Time:<\/strong>\n <\/td>\nMonday, October 26, 2026; 12:00 \u2013 12:45 p.m. CET<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\u00a0<\/td>\nMetastatic NSCLC<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nRinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide: A Global Phase 3 Study in mCRPC Patients\u00a0Previously Treated With Abiraterone Acetate (Himalayas-1)<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n2303TiP<\/td>\n<\/tr>\n
\n Session Date & Time:<\/strong>\n <\/td>\nFriday, October 23, 2026; 3:15 \u2013 4:00 p.m. CEST<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\n <\/td>\nMetastatic Prostate Cancer<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nRinzimetostat, a Next-Generation PRC2 Inhibitor, Enhances Luminal Fate and AR Signaling While Restricting Lineage\u00a0Plasticity in Preclinical Models and Demonstrates Mechanistic
Proof-of-Concept in Samples From Patients with mCRPC<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n1128eP<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\u00a0<\/td>\nDevelopmental Therapeutics<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Full abstracts will be available for public viewing via the ESMO Congress website on October 19, 2026.<\/p>\n

\n About ORIC Pharmaceuticals, Inc. <\/strong>
\n
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by Overcoming Resistance In Cancer<\/em>. ORIC\u2019s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to\u00a0www.oricpharma.com<\/u><\/a>, and follow us on\u00a0X<\/u><\/a>\u00a0or\u00a0LinkedIn<\/u><\/a>.<\/p>\n

\n Contact:
<\/strong>Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com<\/u><\/a>
info@oricpharma.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. Poster presentation details: Title: Enozertinib (ORIC-114), … <\/p>\n

Continue reading “ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-982776","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. Poster presentation details: Title: Enozertinib (ORIC-114), … Continue reading "ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T13:41:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026\",\"datePublished\":\"2026-07-20T13:41:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\"},\"wordCount\":355,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\",\"name\":\"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=\",\"datePublished\":\"2026-07-20T13:41:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk","og_description":"Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. Poster presentation details: Title: Enozertinib (ORIC-114), … Continue reading \"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-20T13:41:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026","datePublished":"2026-07-20T13:41:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"},"wordCount":355,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","name":"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=","datePublished":"2026-07-20T13:41:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NDQ4OSM3NzEyNzM4IzIwODA4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ORIC\u00ae Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=982776"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982776\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=982776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=982776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=982776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}